Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP238158.RAf3OAsmiD_hfnWpElKuQQi1bFFcKmJZvJVa9QvIvXQb4130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP238158.RAf3OAsmiD_hfnWpElKuQQi1bFFcKmJZvJVa9QvIvXQb4130_provenance.
• NP887103.RAjhyObn8zfidJtxuslfJityFTTXc7kbvYdWq6FokpF6Q130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP887103.RAjhyObn8zfidJtxuslfJityFTTXc7kbvYdWq6FokpF6Q130_provenance.
• NP839206.RAsBA392mWOjbZAsJRNEEBffQkqA-LzoGX1LIWskP_ot0130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP839206.RAsBA392mWOjbZAsJRNEEBffQkqA-LzoGX1LIWskP_ot0130_provenance.
• NP222906.RACfre7voYb0RerdePs2xzP14ZmYX5km1cJ6ZWPdFSzO4130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP222906.RACfre7voYb0RerdePs2xzP14ZmYX5km1cJ6ZWPdFSzO4130_provenance.
• NP499895.RAFaCj2y_A_yi6u_JX27g4RRRxyWzRVTVyaQrLapNouPI130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499895.RAFaCj2y_A_yi6u_JX27g4RRRxyWzRVTVyaQrLapNouPI130_provenance.
• NP533745.RA92BKCJR3OiCjbThlaGq8FoNCjPL3jHRvv2OlyicOThM130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP533745.RA92BKCJR3OiCjbThlaGq8FoNCjPL3jHRvv2OlyicOThM130_provenance.
• NP779251.RA60AX0INmShI5Iw_io1Wp73HZUHtwJePZPpFWeuff0g8130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP779251.RA60AX0INmShI5Iw_io1Wp73HZUHtwJePZPpFWeuff0g8130_provenance.
• NP627753.RAJWwZw0dodB7BQsQxophhJ0r7Bn_fzv-tswIJuR40cTE130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627753.RAJWwZw0dodB7BQsQxophhJ0r7Bn_fzv-tswIJuR40cTE130_provenance.
• NP222958.RAVIkk6D0S9EeAEPF6SU_j4Xq29bKEWcWxlDWCJTsbK3o130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP222958.RAVIkk6D0S9EeAEPF6SU_j4Xq29bKEWcWxlDWCJTsbK3o130_provenance.
• NP1011402.RAxdNYk4WdYnLJYBd_9VLwnJlbRbD5XEXDi939XVLrJkw130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1011402.RAxdNYk4WdYnLJYBd_9VLwnJlbRbD5XEXDi939XVLrJkw130_provenance.
• NP1011403.RA-zSANkip8b0O7gpZoEdYYi-ZOwf7FI0ku7PkAfuXhFc130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1011403.RA-zSANkip8b0O7gpZoEdYYi-ZOwf7FI0ku7PkAfuXhFc130_provenance.
• NP412067.RA5P5QGV_la1rLhCF_HbYz9JmOeDidwTgXYWpCIDElXZY130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412067.RA5P5QGV_la1rLhCF_HbYz9JmOeDidwTgXYWpCIDElXZY130_provenance.
• NP412068.RA7XPG8LRx6RTZnIolxFwOTXcHfgB1ncEnuNEn5gtUpEM130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412068.RA7XPG8LRx6RTZnIolxFwOTXcHfgB1ncEnuNEn5gtUpEM130_provenance.
• NP412066.RAQL7shUUyGlTuSIGF404tABFyoWQnMg0LR2Od0b1xSas130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412066.RAQL7shUUyGlTuSIGF404tABFyoWQnMg0LR2Od0b1xSas130_provenance.
• NP412070.RAUCZKk0A0oLeZcFiXcnsoaBJD8gmO3V4uTkyg-_PIQ0I130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412070.RAUCZKk0A0oLeZcFiXcnsoaBJD8gmO3V4uTkyg-_PIQ0I130_provenance.
• NP222883.RAsNb6yo2XNwzrYbNVtuBW1Z88P7zfNtVjY76Wytk2mtI130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP222883.RAsNb6yo2XNwzrYbNVtuBW1Z88P7zfNtVjY76Wytk2mtI130_provenance.
• assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1011406.RAIFHAvTyMkkp2-ktVjpnevyMjtpNlCyyv499qdpIoV3I130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1011406.RAIFHAvTyMkkp2-ktVjpnevyMjtpNlCyyv499qdpIoV3I130_provenance.
• NP412071.RAMU43IKQ_K93hH-6HikMI8dMYO393HbqnrrETnaHuOI0130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412071.RAMU43IKQ_K93hH-6HikMI8dMYO393HbqnrrETnaHuOI0130_provenance.
• NP412069.RAgMgmgqVfYMrItY9rBGZMz0uzz73ZHIDxlTwni47F45Y130_assertion description "[FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412069.RAgMgmgqVfYMrItY9rBGZMz0uzz73ZHIDxlTwni47F45Y130_provenance.